Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 67,9 M
EBIT 2016 3,97 M
Net income 2016 -9,56 M
Debt 2016 49,8 M
Yield 2016 -
Sales 2017 94,7 M
EBIT 2017 13,3 M
Net income 2017 -0,31 M
Debt 2017 60,2 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,79x
EV / Sales2017 4,98x
Capitalization 411 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
10/20Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
09/13 TELIGENT, INC. : To Present At Morgan Stanley Global Healthcare Conference On Se..
09/01 TELIGENT : Announces Health Canada Approval Of Gentamicin Injection USP
08/25 TELIGENT, INC. : Announces Health Canada Approval Of Three Baclofen Injection Pr..
08/23 TELIGENT, INC. : Announces Health Canada Approval Of Gentamicin Injection USP
08/08 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
08/02 TELIGENT : Sanders Morris Harris buys $15,297,383 stake in Teligent Inc
07/29 TELIGENT : reports 2Q loss
07/28 TELIGENT, INC. : Announces Second Quarter 2016 Results
07/28 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
07/19 TELIGENT : Advances $50 Million Facility Expansion
More news
Sector news : Pharmaceuticals - NEC
09:39p MYLAN : faces scrutiny over EpiPen profit data shown to Congress
05:36pDJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
05:36pDJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,75 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%411
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results